TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
Brief Summary: This research is being done to compare the physical and quality of life benefits of two different types of exercise- tai chi versus strength training- for female cancer survivors who have had chemotherapy. Each exercise- tai chi and strength training- will be compared to participants in a group that performs flexibility and relaxation exercises, which is expected to have different benefits than either tai chi or strength training.


Options:
A: Arm Label: Arm I (strength training); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Questionnaire Administration | Arm Label: Arm II (tai chi); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Questionnaire Administration | Arm Label: Arm III (control); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Intervention, Other: Questionnaire Administration | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Arm I (strength training) | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Arm II (tai chi) | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Arm III (control) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (strength training), Arm II (tai chi), Arm III (control)
B: Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): N/A
C: Arm Label: Football; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Football | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Football; Assigned to Arm(s): Football
D: Arm Label: Exercising Together; Type: EXPERIMENTAL; Interventions: Behavioral: Randomized Exercise Intervention | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Randomized Exercise Intervention | Intervention Type: BEHAVIORAL; Name: Randomized Exercise Intervention; Assigned to Arm(s): Exercising Together | Intervention Type: BEHAVIORAL; Name: Randomized Exercise Intervention; Assigned to Arm(s): Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Probiotics and Allergic Diseases
Brief Summary: Many studies had demonstrated that probiotics could be applied in the prevention and adjuvant treatment for allergic diseases. In this study, we investigate the effects of Lactobacillus paracasei GMNL-133(LP), Lactobacillus fermentum GM-090 (LF), and Lactobacillus paracasei GMNL-133(LP) with Lactobacillus fermentum GM-090 (LF) combination products used for adjuvant treatment of atopic dermatitis and asthma.


Options:
A: Arm Label: LP GMNL-133 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 capsule | Arm Label: LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LF GM-090 capsule | Arm Label: LP GMNL-133+LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 +LF GM-090 capsule | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 capsule; Assigned to Arm(s): LP GMNL-133 group | Intervention Type: BIOLOGICAL; Name: LF GM-090 capsule; Assigned to Arm(s): LF GM-090 group | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 +LF GM-090 capsule; Assigned to Arm(s): LP GMNL-133+LF GM-090 group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Lactobacillus reuteri; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu); Assigned to Arm(s): N/A
D: Arm Label: Infants drink formula added with LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Casein hydrolysate added with LGG | Arm Label: Infants drink casein hydrolysate without LGG; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Infants drink casein hydrolysate without LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Casein hydrolysate added with LGG; Assigned to Arm(s): Infants drink formula added with LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Infants drink casein hydrolysate without LGG; Assigned to Arm(s): Infants drink casein hydrolysate without LGG

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (The BRDME Study)
Brief Summary: The primary objective is to demonstrate the non-inferiority of bevacizumab to ranibizumab in the treatment of patients with DME (OCT central area thickness \> 275 μm) as determined by the change in best-corrected visual acuity (BCVA) in the study eye from baseline to month 6.


Options:
A: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.3 mg intravitreal ranibizumab | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: 2.0 mg intravitreal aflibercept | Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: 1.25 mg intravitreal bevacizumab | Intervention Type: DRUG; Name: 2.0 mg intravitreal aflibercept; Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: 1.25 mg intravitreal bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: 0.3 mg intravitreal ranibizumab; Assigned to Arm(s): Ranibizumab
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
C: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Bevacizumab | Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Bevacizumab, Ranibizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab, Ranibizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunctive Renal Denervation to Modify Hypertension and Sympathetic Tone as Upstream Therapy in the Treatment of Atrial Fibrillation
Brief Summary: The objective of the H-FIB trial is to determine the role of renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
B: Arm Label: Denervation; Type: EXPERIMENTAL; Interventions: Device: Ardian Symplicity™ Catheter | Intervention Type: DEVICE; Name: Ardian Symplicity™ Catheter; Assigned to Arm(s): Denervation
C: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Device: Boston Scientific Vessix Renal Denervation System | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Boston Scientific Vessix Renal Denervation System; Assigned to Arm(s): Intervention arm
D: Arm Label: renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal sympathetic denervation, Drug: drug, Procedure: Direct-Current Cardioversion | Arm Label: drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: drug | Intervention Type: PROCEDURE; Name: renal sympathetic denervation; Assigned to Arm(s): renal sympathetic denervation | Intervention Type: DRUG; Name: drug; Assigned to Arm(s): drug therapy, renal sympathetic denervation | Intervention Type: PROCEDURE; Name: Direct-Current Cardioversion; Assigned to Arm(s): renal sympathetic denervation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunctive Renal Denervation to Modify Hypertension and Sympathetic Tone as Upstream Therapy in the Treatment of Atrial Fibrillation
Brief Summary: The objective of the H-FIB trial is to determine the role of renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal denervation (Symplicity Catheter System), Diagnostic Test: Renal angiogram | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Diagnostic Test: Renal angiogram | Intervention Type: DEVICE; Name: Renal denervation (Symplicity Catheter System); Assigned to Arm(s): Renal Denervation | Intervention Type: DIAGNOSTIC_TEST; Name: Renal angiogram; Assigned to Arm(s): Control group, Renal Denervation
B: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Device: Boston Scientific Vessix Renal Denervation System | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Boston Scientific Vessix Renal Denervation System; Assigned to Arm(s): Intervention arm
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
D: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Brief Summary: The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: AIN457 150 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 150 mg - Start of relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: AIN457 300 mg - Start of Relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Open Label (OL); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Intervention Type: DRUG; Name: AIN457 150 mg; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR) | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg - Fixed Interval (FI), AIN457 300 mg - Open Label (OL), AIN457 300 mg - Start of Relapse (SoR) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR), AIN457 300 mg - Start of Relapse (SoR)
D: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Brief Summary: The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.


Options:
A: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
B: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Brief Summary: The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.


Options:
A: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
C: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
D: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Brief Summary: The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.


Options:
A: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
C: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
D: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab

Answer: B